SKYE Stock Forecast & Price Target

Skye Bioscience Inc. is advancing the development of nimacimab, an innovative therapy targeting peripheral CB1 receptors, which shows promise for broader applications in metabolic liver disease and obesity due to its favorable biomarker improvements and liver-targeting properties. This potential expansion into areas beyond initial indications, similar to the progression of ezetimibe, suggests a strategic advantage in addressing comprehensive cardiometabolic risks. Additionally, the gastrointestinal tolerability of nimacimab compared to GLP-1 agonists supports the potential for sustained patient adherence, further enhancing the therapeutic prospects and commercial viability of the company's clinical pipeline.

Skye Bioscience has consistently incurred operating losses since its inception, which indicates potential challenges in achieving profitability for several years. Furthermore, if the Phase 2a trial for nimacimab yields limited efficacy or safety concerns, it could render the drug non-viable for obesity treatment, leading to a significant decline in stock value, possibly down to cash value. Lastly, the noted translational gaps in safety and tolerability for CB1 antagonists, particularly due to their central nervous system penetration, add an additional layer of risk to the company's clinical assets and overall market outlook.